Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced ...

Harrow’s Iheezo cuts eye-injection discomfort by more than half

<?xml encoding="utf-8" ?> Ophthalmic disease management company Harrow Inc. HROW on Thursday shared outcomes from a ...

Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study

Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal ...
Ophthalmology Times

Evaluation of a topical anesthetic gel reduces patient discomfort after intravitreal injections

IHEEZO is a topical ester anesthetic indicated for ocular surface anesthesia not for injection or intraocular use. Patients ...

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal ...